Zone7 secures $8 million in Series A to scale AI-driven human performance offering


Eyal Eliakim and I are extremely proud to announce this milestone. The work continues as the company grows, but this is the right time to acknowledge that there’s an entire village contributing to this journey.

We are extremely grateful for:

  • Our clients – thank you for your trust in our team and product.
  • Our team – employees, advisors, suppliers and family members 🙂 every win is a result of your hard work.
  • Our phenomenal investors – thank you for for believing in this/us and for unwavering support during the good and bad days. A special thank you to Blumberg Capital for leading this round, rolling up their sleeves from day-1 and REALLY working with us to take Zone7 to the next level.

Onwards and upwards.

– Tal Brown, CEO Zone7


Zone7, has announced an $8 million Series A round of funding led by Blumberg Capital with participation from previous investors Resolute Ventures, UpWest, PLG Ventures and Joyance Partners. Additional investors in the round included Value Stream Ventures, Alumni Ventures and New York based J Ventures.

A proprietary AI solution, Zone7 analyzes disparate datasets, uncovers patterns invisible to the human eye, and makes proactive recommendations to improve output, detect burnout risk, and mitigate injuries. The technology tackles the significant costs incurred by professional sports injuries ($40 billion per annum), as well as the large losses sustained by workplace injuries across the economy ($170 billion per annum).

“We are honored to have such a decorated group of investors behind Zone7, as we continue our steady growth across teams, sports, and industries,” said Tal Brown, CEO and Co-Founder. “Our product demonstrated its positive impact on athlete wellbeing and resiliency throughout the COVID pandemic. With this new capital, we look forward to growing our team, doubling down on our success in sports, and continuing to scale Zone7 adoption in new sectors where fatigue, injury, or burnout carry significant risk.”

Zone7’s device agnostic platform has already developed an extensive client portfolio in professional sports and is now used by elite organizations across the EPL, MLS, NFL, La Liga, Serie A, PRO14, Premiership Rugby, among other leagues, to attain greater in-competition success. The technology is also actively applied in hospitals for healthcare workforce management.

“I have seen firsthand the benefits that coaches, physios, hospital staff, and military personnel are deriving from Zone7, especially throughout the pandemic and its disruption of schedules, rest time and workload,” added Roger Mitchell, Executive Advisor to Zone7 and former CEO of the Scottish Premier League. “Zone7 is in a fantastic position to scale, and we are excited to build a larger team to help realize that potential.”

The Series A caps off a strong year of client growth for Zone7, which has quadrupled its number of professional sports clients across the U.S. and Europe. The company also developed new partnerships across contact sports and cycling, expanded into more healthcare settings, and has made strategic hires to support priorities including service delivery within soccer.

“Tal and his team have developed a truly unique machine learning risk management solution, one which complements our portfolio of AI and big data analysis companies,” said Bruce Taragin, Managing Director at Blumberg Capital and Zone7’s newest board member. “The company’s success stories in sports speak for themselves, and we look forward to working closely with the Zone7 team to expand into other areas of the economy and throughout their growth journey.”

Zone7 previously announced $2.5 million in seed funding in 2019, bringing its current total funding to more than $10 million. Other decorated Zone7 investors from the sports and wellbeing space include professional athletes Kristaps Porzingis (Dallas Mavericks), Jordi Cruyff (FC Barcelona), Phil Jones (Manchester United), and John Colquhoun (formerly of Heart of Midlothian FC).

About Blumberg Capital
Blumberg Capital is an early-stage venture capital firm that partners with passionate entrepreneurs to innovate, build, and scale successful technology companies. The firm specializes in leading Seed and Series A rounds collaborating with angel investors, other venture capital firms and strategic partners. The Blumberg Capital team are active investors and board members – operating as an extension of the entrepreneurs’ network. Blumberg Capital is headquartered in San Francisco with team members in Tel Aviv, New York, and Miami. For more information, please visit